Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

MigC interacts with and decreases the activity of MurD. by Jeanette M. Critchlow (21553796)

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

TH5487 decreases RSV-induced release of lactose dehydrogenase (LDH). by Lang Pan (5145221)

GLS inhibition decreases IL-1β secretion <i>in vitro</i>. by Bárbara Ponzilacqua-Silva (17002156)

Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Effects of GJE extract treatment decreased serum ALT and AST levels. by Natnicha Suttawong (22367172)

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

Subjects:

Prolonged starvation leads to a delay in cell cycle re-entry and decrease in H3K27ac in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

“…During starvation (T_5ds, T_20ds), MFI levels of H3K27ac progressively decreased <b>(F)</b> while levels H3K27me3 did not change significantly <b>(G)</b>. …”

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”